Pharmacokinetics of a Slower Clearing Tissue Plasminogen Activator Variant, TNK-tPA, in Patients with Acute Myocardial Infarction
暂无分享,去创建一个
T. W. Love | E. Braunwald | C. Cannon | E. Braunwald | N. Modi | S. Eppler | J. Breed | T. Love
[1] E. Braunwald,et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.
[2] B. Keyt,et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. , 1995, Circulation.
[3] K. Gough,et al. Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party , 1995 .
[4] C. Cannon,et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1994, Journal of the American College of Cardiology.
[5] J. Mehta,et al. Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction. , 1994, The American journal of cardiology.
[6] B. Keyt,et al. A Long‐Half‐life and Fibrin‐Specific Form of Tissue Plasminogen Activator in Rabbit Models of Embolic Stroke and Peripheral Bleeding , 1994, Stroke.
[7] B. Keyt,et al. Comparative Thrombolytic Properties of Tissue-Type Plasminogen Activator and of a Plasminogen Activator Inhibitor-1 -Resistant Glycosylation Variant, in a Combined Arterial and Venous Thrombosis Model in the Dog , 1994, Thrombosis and Haemostasis.
[8] D. Botstein,et al. A faster-acting and more potent form of tissue plasminogen activator. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[9] Gusto Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.
[10] B. Keyt,et al. A Slow Clearing, Fibrin-Specific, PAI-1 Resistant Variant of t-PA (T103N, KHRR 296-299 AAAA) , 1993, Thrombosis and Haemostasis.
[11] B. Keyt,et al. A Variant of t-PA (T103N, KHRR 296-299 AAAA) that, by Bolus, Has Increased Potency and Decreased Systemic Activation of Plasminogen , 1993, Thrombosis and Haemostasis.
[12] D. Lipkin,et al. Effectiveness and safety of a single intravenous Bolus injection of tissue-type plasminogen activator in acute myocardial infarction , 1992 .
[13] J. Wójcik,et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. , 1992, Journal of the American College of Cardiology.
[14] U. Tebbe,et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS) , 1992, Journal of the American College of Cardiology.
[15] K. Strein,et al. Pharmacokinetics of the Novel Recombinant Plasminogen Activator BM 06.022 in Rats, Dogs, and Non-human Primates , 1992 .
[16] C. Wilson,et al. Effectiveness of double bolus alteplase in the treatment of acute myocardial infarction. , 1991, The American journal of cardiology.
[17] F. Dunn,et al. A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. , 1991, British heart journal.
[18] B. Sobel,et al. Thrombolysis and Myocardial Infarction , 1991 .
[19] E. Braunwald. Enhancing thrombolytic efficacy by means of "front-loaded" administration of tissue plasminogen activator. , 1989, Journal of the American College of Cardiology.
[20] U. Tebbe,et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.
[21] E. Seifried,et al. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. , 1989, The American journal of cardiology.
[22] E. Seifried,et al. Pharmacokinetics and Haemostatic Status During Consecutive Infusions of Recom binant Tissue-Type Plasminogen Activator in Patients with Acute Myocardial Infarction , 1989, Thrombosis and Haemostasis.
[23] G. Larsen,et al. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. , 1989, Blood.
[24] M. Simoons,et al. Thrombolytic therapy in acute myocardial infarction. , 1989, Annual review of medicine.
[25] B. Smedsrød,et al. Tissue Plasminogen Activator is Endocytosed by Mannose and Galactose Receptors of Rat Liver Cells , 1988, Thrombosis and Haemostasis.
[26] E. Topol,et al. Monitoring of Hemostasis Parameters During Coronary Thrombolysis with Recombinant Tissue-Type Plasminogen Activator , 1988, Thrombosis and Haemostasis.
[27] B. Reavy,et al. A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain. , 1988, The Journal of biological chemistry.
[28] M. Gottwik,et al. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). , 1988, Journal of the American College of Cardiology.
[29] G. Larsen,et al. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. , 1988, Blood.
[30] E. Seifried,et al. Comparison of Specific Antibody, D-Phe-Pro-Arg-CH2Cl and Aprotinin for Prevention of In Vitro Effects of Recombinant Tissue-Type Plasminogen Activator on Haemostasis Parameters , 1987, Thrombosis and Haemostasis.
[31] D. Collen,et al. Measurement of free, one-chain tissue-type plasminogen activator in human plasma with an enzyme-linked immunosorbent assay based on an active site-specific murine monoclonal antibody. , 1987, Blood.
[32] M. Mohler,et al. D-Phe-Pro-Arg-Chloromethylketone: Its Potential Use in Inhibiting the Formation of In Vitro Artifacts in Blood Collected During Tissue-Type Plasminogen Activator Thrombolytic Therapy , 1986, Thrombosis and Haemostasis.
[33] I. Palacios,et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. , 1986, Circulation.
[34] D. Collen,et al. Assay of Human Tissue-Type Plasminogen Activator (t-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies to t-PA , 1985, Thrombosis and Haemostasis.
[35] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.
[36] P. Wallén,et al. An Enzyme Linked Immunosorbent Assay for Determination of Tissue Plasminogen Activator Applied to Patients with Thromboembolic Disease , 1983, Thrombosis and Haemostasis.
[37] Leon Shargel,et al. Applied biopharmaceutics and pharmacokinetics , 1980 .